Last reviewed · How we verify
Tacrolimus BID
Tacrolimus is an immunosuppressive drug that works by inhibiting calcineurin, which is necessary for the activation of T-lymphocytes.
Tacrolimus is an immunosuppressive drug that works by inhibiting calcineurin, which is necessary for the activation of T-lymphocytes. Used for Prophylaxis of organ rejection in patients receiving allogeneic organ transplants.
At a glance
| Generic name | Tacrolimus BID |
|---|---|
| Also known as | Prograf, Tacrocell |
| Sponsor | Rabin Medical Center |
| Drug class | Calcineurin inhibitor |
| Target | Calcineurin |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
By inhibiting calcineurin, tacrolimus prevents the transcription of interleukin-2 (IL-2), a cytokine that promotes T-lymphocyte proliferation and activation. This results in a decrease in the immune response and reduces the risk of organ rejection in transplant patients.
Approved indications
- Prophylaxis of organ rejection in patients receiving allogeneic organ transplants
Common side effects
- Diarrhea
- Nausea
- Headache
- Tremor
- Hypertension
Key clinical trials
- Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations (PHASE2)
- Neurocognitive Function Changes With Extended-Release Tacrolimus Among Older Kidney Transplant Recipients (PHASE4)
- Evaluation of the Benefits of Administering Immunosuppressive Drugs as Single Daily Doses Over the First Year After Liver Transplantation (EASY) (PHASE4)
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
- De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis (PHASE2)
- Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS) (PHASE2)
- Tacrolimus Toothpaste for Management of Oral Chronic Graft vs. Host Disease (cGVHD) (PHASE1)
- A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |